Summit Therapeutics (SMMT) Profit After Tax (2016 - 2025)
Historic Profit After Tax for Summit Therapeutics (SMMT) over the last 9 years, with Q3 2025 value amounting to -$231.8 million.
- Summit Therapeutics' Profit After Tax fell 31204.71% to -$231.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$921.6 million, marking a year-over-year decrease of 36858.94%. This contributed to the annual value of -$221.3 million for FY2024, which is 6400.96% up from last year.
- Per Summit Therapeutics' latest filing, its Profit After Tax stood at -$231.8 million for Q3 2025, which was down 31204.71% from -$565.7 million recorded in Q2 2025.
- Summit Therapeutics' 5-year Profit After Tax high stood at -$19.2 million for Q4 2022, and its period low was -$565.7 million during Q2 2025.
- For the 4-year period, Summit Therapeutics' Profit After Tax averaged around -$107.3 million, with its median value being -$56.3 million (2024).
- Per our database at Business Quant, Summit Therapeutics' Profit After Tax surged by 54.71% in 2023 and then plummeted by 83683.53% in 2025.
- Quarter analysis of 4 years shows Summit Therapeutics' Profit After Tax stood at -$19.2 million in 2022, then tumbled by 90.17% to -$36.6 million in 2023, then crashed by 67.37% to -$61.2 million in 2024, then tumbled by 278.73% to -$231.8 million in 2025.
- Its Profit After Tax stands at -$231.8 million for Q3 2025, versus -$565.7 million for Q2 2025 and -$62.9 million for Q1 2025.